Results for 'tumour growth inhibition'
Leadership Lab: 10 Ways Executives Can Stay Visible, Valuable Between Jobs
Oct 22nd • 5 mins read
Leadership Lab: How To Spot When Employees Are About To Walk Away
Oct 22nd • 7 mins read
Loose Regulatory Standards Portend a New Era of Imprecision Oncology
Dec 1st • 4 mins read
Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology
Nov 20th • 12 mins read
Liquid biopsy in oncology: a consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology
Sep 26th • 17 mins read
Leveraging existing data to contextualize phase II clinical trial findings in oncology
Sep 21st • 3 mins read
Lessons learnt from scoring adjuvant colon cancer trials and meta-analyses using the ESMO-Magnitude of Clinical Benefit Scale V.1.1
Sep 6th • 17 mins read
Tumor Growth Dynamic Modeling in Oncology Drug Development and Regulatory Approval: Past, Present, and Future Opportunities
Jun 26th • 18 mins read
Access to Novel Drugs for Non-Small Cell Lung Cancer in Central and Southeastern Europe: A Central European Cooperative Oncology Group Analysis
Nov 24th • 10 mins read
In Vitro-to-In Vivo Extrapolation of Transporter Inhibition Data for Drugs Approved by the US Food and Drug Administration in 2018
Jan 25th • 12 mins read
EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies
Jan 20th • 20 mins read
Publication statuses of clinical trials supporting FDA-approved immune checkpoint inhibitors: a meta-epidemiological investigation
Oct 24th • 18 mins read
Liquid biopsy in oncology: a consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology
Sep 26th • 16 mins read